AbCellera Biologics Inc.
ABCL · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $75.1M | $28.8M | +161% |
| Operating income | −$217M | −$315M | +31.0% |
| Net income | −$146M | −$163M | +10.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $10.6M | $9.00M | +17.8% |
| Operating income | −$53.3M | −$76.3M | +30.1% |
| Net income | −$40.8M | −$57.1M | +28.5% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was AbCellera's revenue in FY2025?
- $75.1M in FY2025 (Fiscal year ended Dec 31, 2025), +161% vs $28.8M a year earlier, per its 10-K filed Feb 2026.
- Was AbCellera profitable in FY2025?
- No: net income was −$146M and operating income −$217M in FY2025.
- What was AbCellera's revenue in Q3 2026?
- $10.6M (+17.8% vs a year earlier), per its Form 10-Q filed Nov 9, 2026.